Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.42 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GRK6 | P43250 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16853377 | 0.88 | SMN1; SMN2 (0.37) | MBOAT4MRGPRX4FFAR1SMN1; SMN2CYP4F2 | |
| SCHEMBL28028553 | 0.83 | CACNA1I (0.44) | MRGPRX4NPC1RAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL10415286 | 0.80 | ABL1 (0.42) | MBOAT4EPHX2NPC1RAB9AL3MBTL1 | |
| SCHEMBL2435333 | 0.78 | KDM4E (0.50) | PTGDR2FFAR1SMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL10817490 | 0.78 | GABRP (0.40) | FFAR1CYP4F2CYP4A11KMT2A | |
| SCHEMBL28028513 | 0.78 | KMT2A (0.46) | SMN1; SMN2CYP4F2CYP4A11MEN1KMT2A | |
| SCHEMBL27847702 | 0.77 | ATM (0.44) | MBOAT4MRGPRX4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30106088 | 0.77 | ATM (0.44) | MBOAT4MRGPRX4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5104455 | 0.77 | KMT2A (0.46) | NPC1RAB9AL3MBTL1SMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL17653965 | 0.77 | KDM4E (0.49) | PTGDR2FFAR1SMN1; SMN2PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339890-A1 | AMINO ALCOHOL COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339890-A1 | AMINO ALCOHOL COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| WO-2023107630-A2 | AMINO ALCOHOL COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107630-A2 | AMINO ALCOHOL COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (UK) | 2017-10-26 | — | — | US | disclosed |
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (UK) | 2017-10-26 | — | — | US | disclosed |
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (UK) | 2017-10-26 | — | — | US | disclosed |
| EP-3083602-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | Pfizer Limited (GB) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015092610-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015092610-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
| CN-103221408-A | Triazine-oxadiazole compounds | NOVARTIS AG | 2013-07-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305857-A1 | N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS | TNNI3, MUSK, MYLK2 | MBOAT4 1709/4885SHMT2 1961/4885PTGDR2 1796/4885 |
| US-20230339890-A1 | AMINO ALCOHOL COMPOUNDS AND USES THEREOF | AADAT, SLC1A2, SLC1A1 | MBOAT4 3611/4885SHMT2 125/4885PTGDR2 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.